Clinical Trial

A Study of Eltrekibart (LY3041658) in Healthy Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to evaluate how eltrekibart is absorbed by the body when it is given under the skin to healthy participants. The study will last about 17 weeks.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-24
Trial Details
NCT Number NCT07545590
Lead Sponsor Eli Lilly and Company
Conditions Healthy
Enrollment 60 participants
Start Date 2026-04-21
Primary Completion 2026-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-06-23